
Cardiologs is a medical technology company founded in 2014 in Paris, focused on leveraging machine learning and cloud technology to enhance cardiac diagnostics. Their flagship product, the Cardiologs Holter Platform, is a cloud-based, vendor-neutral arrhythmia diagnostic software powered by Artificial Intelligence. It is the first medical device powered by deep learning technology to receive CE marking and FDA clearance. The company processes over 140 million ECGs, representing 20,000 years of ECG signal, and diagnoses over 2 million patients annually. Cardiologs aims to make cardiology diagnostics scalable and accessible globally, providing tools for clinicians to manage the increasing demand for cardiac diagnosis. They are actively recruiting, emphasizing a passionate and innovative work environment.

Cardiologs is a medical technology company founded in 2014 in Paris, focused on leveraging machine learning and cloud technology to enhance cardiac diagnostics. Their flagship product, the Cardiologs Holter Platform, is a cloud-based, vendor-neutral arrhythmia diagnostic software powered by Artificial Intelligence. It is the first medical device powered by deep learning technology to receive CE marking and FDA clearance. The company processes over 140 million ECGs, representing 20,000 years of ECG signal, and diagnoses over 2 million patients annually. Cardiologs aims to make cardiology diagnostics scalable and accessible globally, providing tools for clinicians to manage the increasing demand for cardiac diagnosis. They are actively recruiting, emphasizing a passionate and innovative work environment.
Founded: 2014 in Paris
Product: Cloud-based, vendor-neutral Holter/ECG diagnostic platform powered by deep-learning AI
Regulatory milestones: First deep-learning-powered device to receive a CE mark; FDA 510(k) clearance (first 2017; pediatric clearance 2021)
Notable funding: Oct 2017: $6.4M; Jan 2020: $15.0M (led by Alven)
Cardiac diagnostics and remote cardiac monitoring (ECG/arrhythmia detection and reporting).
2014
Medical technology
$6.4M
Reported financing announced Oct 5, 2017
$15.0M
Press release announcing $15M Series A; company noted participation from existing investors
€1.0M
€480k + $100k
Summarized as early angel rounds in 2014–2015
“Lead investor on Jan 2020 round: Alven; participating investors (per company disclosure) include Bpifrance, ISAI, Kurma Diagnostics, Idinvest Partners, Paris Saclay Seed Fund.”